Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Hiroki Osumi1, Eiji Shinozaki1*, Mitsukuni Suenaga1, Yosuke Kumekawa1, Mariko Ogura2, Masato Ozaka1, Satoshi Matsusaka1, Keisho Chin1, Noriko Yamamoto3 and Nobuyuki Mizunuma1

Abstract

Background: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 antibody positivity. This study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.

Methods: Ninety patients treated with fluoropyrimidine, oxaliplatin plus bevacizumab as first-line chemotherapy were enrolled, including 70 whose KRAS genotype was revealed at the beginning of treatment. Before chemotherapy initiation, the serum p53 antibody level was quantified by enzyme-linked immunosorbent assay using MESACUP® anti-p53 test kits. The cutoff value for positivity was 1.3 U/mL, as calculated previously. The KRAS genotype of the tumor samples was analyzed using the Luminex® assay.

Results: Overall response rates of Response Evaluation Criteria in Solid Tumors criteria were 77.7 % (42/54) in anti-p53–negative patients and 69.4 % (25/36) in anti-p53–positive patients. The odds ratio was 1.07. Median overall survival was 36.1 months in the anti-p53–positive patients, and not available in the anti-p53–negative patients (hazard ratio, 0.81; 95 % confidence interval, 0.37–1.77; P = 0.61). The corresponding values for median progression-free survival were 13.3 months and 14.6 months (hazard ratio, 0.69; 95 % confidence interval, 0.41–1.17; P = 0.17), respectively.

Conclusions: Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.

Keywords: Anti-p53 antibody, KRAS, Metastatic colorectal cancer, First-line chemotherapy

Background

In 1988, Vogelstein et al. proposed a multistage theory of carcinogenesis known as the adenoma–carcinoma sequence, in which colorectal cancer (CRC) arises because of mutations that activate multiple oncogenes and inactivate tumor-suppressor genes. These mutations accumulate in the normal colonic epithelial cells and cause adenomas. TP53 mutations were proposed as the driver mutations in colorectal carcinogenesis [1].

Furthermore, the TP53 gene mutation is widely known as an important determinant of impaired chemosensitivity [2]. Approximately 40–50 % of CRC lesions are reported to carry either a mutation in TP53 and/or loss of a heterozygote at chromosome 17q, where TP53 is located [3]. Several in vitro studies have reported a relationship between TP53 mutation status and sensitivity to a number of cytotoxic agents, including fluoropyrimidines [4]. Furthermore, the presence of a TP53 mutation in tumors is

* Correspondence: eiji.shinozaki@jfcr.or.jp
1Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 A intrigue, Koto-ku, Tokyo 135-8550, Japan
Full list of author information is available at the end of the article

© 2015 Osumi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
associated with shorter patient survival compared with the presence of wild-type TP53.

p53 is a tumor-suppressor protein encoded by the TP53 gene in humans. Mutations commonly result in expression of proteins with abnormal conformation, which is readily detected as a p53 overexpression by immunohistochemistry (IHC). Furthermore, p53 is crucially involved in the control of the cell cycle and apoptosis and is also frequently altered in CRC. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with the presence of serum anti-p53 antibodies [5]. Anti-p53 antibodies are independent prognostic factors in esophageal and ovarian cancer patients treated with chemotherapy [6]. Thus, the presence of serum p53 antibodies could theoretically predict chemoresistance in metastatic CRC (mCRC) treated with chemotherapy. However, no reports showed about the relationship between anti-p53 antibody and chemosensitivity in mCRC patients.

On the other hand, potential biomarkers include mutations in KRAS and BRAF, which result in constitutive signaling through the oncopgenic Ras/Raf/MEK/ERK pathway. Patients carrying tumors with KRAS mutations are also reported to have a poorer prognosis. For example, TP53 mutation in combination with KRAS mutation at codon 13 are associated with a worse prognosis in CRC [7]. However, no reports showed about the relationship between anti-p53 antibody and KRAS mutation.

Therefore, we investigated the relationship between anti-p53 antibody and KRAS genotype and whether the anti-p53 antibody status, IHC of p53 protein status and KRAS genotype are correlated to chemosensitivity and prognostic factors such as overall survival (OS) and progression-free survival (PFS) in mCRC patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy.

Methods
This study has been performed in accordance with the Declaration of Helsinki. The cancer Institute Hospital of Japanese Foundation for Cancer Research, Institutional Review Board approved this study (Registry number: 1278). We obtained a comprehensive written informed consent about the research before chemotherapy was started.

Study population
We enrolled 90 patients who confirmed mCRC and received first-line chemotherapy (FOLFOX or XELOX with Bev) at the Cancer Institute Hospital between January 2009 and November 2010, and measured anti-p53 antibody before receiving first-line chemotherapy.

Treatment and follow-up
The FOLFOX regimen was administered as follows: oxaliplatin on day 1 at a dose of 85 mg/m² as a 2-h infusion concurrent with leovofolinic acid at 200 mg/m²/day, followed by bolus 5-fluouracil (5-FU) at 400 mg/m² and a 22-h infusion of 5-FU at 2400 mg/m² for 2 consecutive days. Bevacizumab was administered at a dose of 5 mg/kg in a 30-min intravenous infusion on day 1 in 2-week cycles.

The XELOX regimen was administered as follows: capecitabine (2000 mg/m², biweekly) plus oxaliplatin (130 mg/m², day 1). Bevacizumab was administered at a dose of 7.5 mg/kg in a 30-min intravenous infusion on day 1 in 3-week cycles.

The treatment was repeated every 2 (or 3) weeks until disease progression or unacceptable toxicity occurred, or until a patient chose to discontinue treatment.

In our hospital, the patients underwent computed tomography scans approximately every 3 months after treatment completion and were regularly assessed for response to chemotherapy and local or distant recurrence. The evaluation was repeated every 3 (or 4) courses, or more frequently in patients with clinically suspected progression. In this study, tumor response was reassessed via computed tomography using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Enzyme Immunoassay for p53antibody, IHC of p53 protein and KRAS genotyping
The serum anti-p53 antibody status was evaluated in each patient before initiation of first-line chemotherapy. The evaluation was performed by enzyme-linked immunosorbent assay (ELISA) using the anti-p53 ELISA Kit (MESACUP, Nagoya, Japan). This kits have been developed with less variation in seropositivity (13–27 %) with intra- and inter-assay coefficient of variation of 1.85–2.37 % and 0.3–3.32 % respectively [8]. For anti-p53 autoantibodies, the cut off for positivity was set at the average value among healthy subjects plus 3 standard deviations or plus 1 standard deviation. The cut-off value for positivity was calculated as 1.3 U/mL, as reported previously [2]. In addition, immunostaining was performed with anti p53 protein antibody (DO-7,DAKO, Glostrup, Denmark) on formalin-fixed paraffin-embedded fragments obtained from those patients from whom adequate tissue samples could be obtained by biopsy or surgical resection. Nuclear staining of tumor cells were judged as positive for p53 protein. The percentage of p53 positive cancer cells was calculated compared with HE staining. The positive rate of ≥70 % was determined as overexpression of p53 protein. The KRAS genotype of the tumor samples was analyzed using the Luminex assay, as previously reported [8]. The sensitivity of KRAS testing by Luminex has been reported to be 10 % [9].
Statistical analysis
Percentages were compared using the chi-square or Fisher’s exact test when appropriate. Quantitative variables were compared using Student’s t test. Follow-up was estimated using the Kaplan-Meier method. The correlation between p53 antibody and the KRAS genotype, IHC of p53 protein were estimated using Pearson’s correlation coefficient. OS and PFS were estimated using the Kaplan-Meier method and compared using the log-rank test. Variables associated with OS or PFS with a P value <0.2 in a univariate analysis were included in a multivariate ascending stepwise Cox regression analysis. In the Cox model, continuous variables were dichotomized. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing). All reported P values were two-sided, and P values <0.05 were considered significant.

Results
Patients characteristics (Table 1)
Between January 2009 and November 2010, 90 patients were referred for first-line chemotherapy for mCRC. Median age of the patients at the time of measuring anti-p53 antibody was 61 years old (±9.1). This cohort was composed of males (38.8 %) and females (61.2 %). Serum anti-p53 antibodies were detected in 40.0 % patients (36/90). IHC analyzed with monoclonal antibodies against

Table 1 Patients characteristics

| Gender, n (%) | ITT population (n = 90) | KRAS wild type | KRAS mutant |
|--------------|-------------------------|----------------|-------------|
|              | p53 antibody | p53 antibody | p53 antibody |
|              | Positive (n = 36) | Negative (n = 54) | Positive (n = 11) | Negative (n = 31) | Positive (n = 13) | Negative (n = 13) |
| Male         | 25 (69.4) | 30 (55.5) | 9 (81.8) | 16 (51.6) | 9 (69.2) | 8 (61.5) |
| Female       | 11 (30.5) | 24 (44.4) | 2 (18.1) | 15 (48.3) | 4 (30.7) | 5 (38.4) |
| Age          | Median (range) | 58.4 (39–74) | 60.9 (39–75) | 57.3 (41–73) | 59.8 (39–71) | 59.3 (39–74) | 61.3 (41–75) |
| <65, n (%)   | 26 (72.2) | 31 (59.2) | 8 (72.7) | 19 (61.2) | 9 (69.2) | 6 (46.1) |
| ≧ 65, n (%)  | 10 (27.7) | 23 (42.5) | 3 (27.2) | 12 (38.7) | 4 (30.7) | 7 (53.8) |
| EOCG PS at base line, n (%) | 0.33 (91.6) | 5 (94.4) | 11 (100) | 30 (96.7) | 9 (69.2) | 12 (92.3) |
| Liver metastasis, n (%) | 1 (3.3) | 3 (5.5) | 0 (0) | 1 (3.1) | 3 (23.0) | 1 (7.7) |
| Lung metastasis, n (%) | 31 (57.4) | 19 (61.2) | 4 (30.7) | 8 (61.5) |
| Lymph node metastasis, n (%) | 26 (46.1) | 17 (54.8) | 8 (61.5) | 4 (30.7) |

ITT intention to treat, PS performance status

Table 2 Clinical response after 1st line chemotherapy

| ITT population (n = 90) | KRAS wild type | KRAS mutant |
|-------------------------|----------------|-------------|
| p53 antibody | p53 antibody | p53 antibody |
| Positive (n = 36) | Negative (n = 54) | Positive (n = 11) | Negative (n = 31) | Positive (n = 13) | Negative (n = 13) |
| Complete Response | 5 (13.8) | 2 (3.7) | 1 (9) | 1 (3.2) | 3 (23) | 0 (0) |
| Partial Response (PR) | 21 (58.3) | 41 (74.0) | 9 (81.8) | 25 (80.6) | 7 (53.8) | 9 (69.2) |
| Stable Disease | 5 (5.5) | 10 (18.5) | 1 (9) | 3 (9.7) | 3 (23) | 4 (30.7) |
| Progressive Disease | 2 (8.3) | 1 (1.8) | 0 (0) | 1 (3.2) | 0 (0) | 0 (0) |
| Not Evaluable | 3 (8.3) | 0 (0) | 0 (0) | 1 (3.2) | 0 (0) | 0 (0) |
| PR in | 26 (72.2) | 43 (79.6) | 10 (91) | 26 (83.8) | 10 (76.9) | 9 (69.2) |
| Odds ratio (95 % CI) | 1.1 (0.55–2.21) | 0.92 (0.3–2.8) | 0.9 (0.23–3.43) |
| P value | 0.87 | 1 | 1 |
p53 of the patients was detected in 63 % (38/60). There was no significant difference in background between the anti-p53–positive and anti-p53–negative groups.

**Correlation between anti-p53 antibody status and clinical outcomes (n = 90)**

Applying RECIST criteria (Table 2), the overall response rate (ORR) was 77.7 % (42/54) in the anti-p53–negative patients and 69.4 % (25/36) in the anti-p53–positive patients. The odds ratio was 1.07. Median OS was 36.1 months in the anti-p53–positive patients and not available (NA) in the anti-p53–negative patients [hazard ratio (HR) 0.81, 95 % confidence interval (CI) 0.37–1.77, \( P = 0.61 \)]. The corresponding values for median PFS were 13.3 months and 14.6 months (HR, 0.69; 95 % CI, 0.41–1.17; \( P = 0.17 \)), respectively (Fig. 1).

**Correlation between IHC of p53 protein status and clinical outcomes (n = 60)**

ORR according to RECIST criteria was 77.7 % (14/18) and 76.1 % (32/42) in the p53 protein negative tumors and the p53 protein positive tumors, respectively. The odds ratio was 1.09. OS was 33.5 months in the p53 protein negative tumors, and NA in the p53 protein positive tumors (HR 0.58, 95 % CI 0.21–1.6, \( P = 0.3 \)). PFS was 13.3 months, and 13.3 months (Table 2), respectively (HR 1.0, 95 % CI 0.51–1.9, \( P = 0.99 \)) (Fig. 2). The estimated correlation between anti-p53 antibody positivity and the IHC of p53 protein positive tumors was 0.32 (95 % CI 0.07–0.53, \( P = 0.012 \)).

---

**Fig. 1 Overall survival and progression-free survival curves according to p53 antibody status for the entire population (n = 90)**

| Median | 95% CI          | HR     | 95% CI   |
|--------|-----------------|--------|----------|
| P53 (–) | 36.1 months    | 0.81   | 0.37–1.77 |
| P53 (+) | 36             |        |          |

**Fig. 2 Overall survival and progression-free survival curves according to IHC of p53 protein status (n = 60)**

| Median | 95% CI          | HR     | 95% CI   |
|--------|-----------------|--------|----------|
| P53 (–) | NA (26.4 to NA) |        |          |
| P53 (+) | 36 months       | 0.58   | 0.21–1.60 |

---

Osumi et al. BMC Cancer (2015) 15:760
Correlation between anti-p53 antibody status and KRAS genotype ($n = 70$) (Table 2)

In the KRAS wild-type ($n = 42$) patients, ORR according to RECIST was 90.9% and 83.8% in the anti-p53–negative patients and anti-p53–positive patients, respectively. Median OS was 35.6 months in all patients, 35.6 months in the anti-p53–negative patients, and NA in the anti-p53–positive patients (HR 0.65, 95% CI 0.18–2.33, $P = 0.5$). The corresponding values for median PFS were 14.6 months in total, 17.9 months, and 16.7 months, respectively (HR 1.06, 95% CI 0.48–2.31, $P = 0.88$) (Fig. 3).

In the KRAS mutant-type ($n = 26$) patients, ORR according to RECIST was 69.2% (9/13) and 76.9% (10/13) in the anti-p53–negative patients and anti-p53–positive patients, respectively. Median OS was 33.8 months in all patients, 13.8 months in the anti-p53–negative patients, and 15.8 months in the anti-p53–positive patients (HR 0.52, 95% CI 0.21–1.28, $P = 0.15$). The corresponding values for median PFS were 14.6 months, 34.3 months, and 26.6 months, respectively (HR 1.18, 95% CI 0.33–4.1, $P = 0.79$) (Fig. 4). The estimated correlation between anti-p53 antibody positivity and the KRAS genotype was 0.037 (95% CI 0.20–0.27, $P = 0.746$).

Univariate and multivariate analysis

In univariate analysis, peritoneal metastasis and multiple metastasis were also significant predictors of OS. On the
other hand, lung metastasis and lymph node metastasis were also significant predictors of PFS. In the multivariate analysis, peritoneal metastasis was significant predictors of OS and lung metastasis and lymph node metastasis were significant predictors of PFS. However both anti-p53 antibody and IHC of p53 protein negativity did not yield any independent predictive factors (Table 3).

Discussion

To our knowledge, this retrospective study is the first to evaluate the predictive significance of the presence of anti-p53 antibodies and its correlation with the KRAS genotype in CRC patients treated with first-line chemotherapy. No correlation was observed between anti-p53 antibody positivity and ORR. Furthermore, no correlation was observed between anti-p53 antibody positivity and the KRAS genotype.

The mechanism underlying anti-p53 auto-antibody production has yet to be revealed but is thought to be associated with the presence of the TP53 mutation and p53 protein overexpression. Anti-p53 autoantibody frequency was then correlated with reported TP53 mutation rates to

| Table 3 Univariate and multivariate analysis |
|---------------------------------------------|
| **Univariate analysis**                      |
| OS                                          |
| Gender (male or female)                      | 0.76 | 0.34 | 1.67 | 0.5 |
| Age (<65 or 2^> 65)                         | 0.98 | 0.94 | 1.03 | 0.5 |
| Performance status (0 or 1)                 | 1.78 | 0.42 | 7.5  | 0.43|
| Resection of primary tumor (yes or no)      | 0.7  | 0.2  | 1.6  | 0.83|
| Ascitis (yes or no)                         | 1.7  | 0.7  | 4.1  | 0.22|
| Liver metastasis (yes or no)                | 1.2  | 0.59 | 2.6  | 0.55|
| Lung metastasis (yes or no)                 | 0.77 | 0.34 | 1.7  | 0.51|
| Lymph metastasis (yes or no)                | 1.9  | 0.86 | 4.2  | 0.1 |
| Multiple metastasis (yes or no)             | 2.5  | 1.1  | 5.9  | 0.03|
| Peritoneal metastasis (yes or no)           | 2.5  | 1.2  | 5.2  | 0.01|
| Anti p53 antibody (positive or negative)    | 0.8  | 0.3  | 1.7  | 0.61|
| IHC of p53 protein (positive or negative)   | 0.58 | 0.21 | 1.6  | 0.3 |
| KRAS (wild or mutant)                       | 1.29 | 0.54 | 2.75 | 0.63|
| PFS                                         |
| Gender (male or female)                      | 1.6  | 0.9  | 3.03 | 0.1 |
| Age (<65 or 65)                             | 0.99 | 0.96 | 1.02 | 0.53|
| Performance status (0 or 1)                 | 1.8  | 0.23 | 2.47 | 0.64|
| Resection of primary tumor (yes or no)      | 1.5  | 0.72 | 3.1  | 0.99|
| Ascitis (yes or no)                         | 0.6  | 0.28 | 1.43 | 0.29|
| Liver metastasis (yes or no)                | 0.54 | 0.28 | 1   | 0.07|
| Lung metastasis (yes or no)                 | 2.8  | 1.59 | 5.2  | 4E-04|
| Lymph metastasis (yes or no)                | 0.47 | 0.26 | 0.85 | 0.01|
| Multiple metastasis (yes or no)             | 0.9  | 0.51 | 1.6  | 0.72|
| Peritoneal metastasis (yes or no)           | 0.73 | 0.37 | 1.45 | 0.27|
| Anti p53 antibody (positive or negative)    | 0.9  | 0.49 | 1.6  | 0.73|
| IHC of p53 protein (positive or negative)   | 1    | 0.51 | 1.9  | 0.99|
| KRAS (wild or mutant)                       | 0.98 | 0.49 | 1.9  | 0.04|

| Multivariate analysis                       |
| OS                                          |
| Peritoneal metastasis (yes or no)           | 2.3  | 1.1  | 5.1  | 0.02|
| PFS                                         |
| Lung metastasis (yes or no)                 | 2.46 | 1.34 | 4.51 | 0.003|
| Lymph metastasis (yes or no)                | 0.5  | 0.28 | 0.97 | 0.04|
determine the association between anti-p53 antibody positivity and the TP53 mutation status (CRC: TP53 mutation 43.3 %, anti p53 antibody positivity 21.4 %). Moderate correlation ($r^2 = 0.45$, correlation 0.59) was found to exist between anti-p53 antibody positivity and the TP53 mutation [10]. Mutational loss of the tumor-suppressor functions of TP53 has been associated with decreased sensitivity to agents inhibiting DNA synthesis, such as 5-FU [11]. These genetic alterations play crucial roles in colorectal carcinogenesis, including DNA damage signaling and the response to platinum-based chemotherapeutic agents.

As mentioned above, preclinical research has indicated that disruptions in the Ras/Raf/MEK/ERK pathway or inactivation of the TP53 tumor-suppressor gene may have clinical relevance to the efficacy of anti-VEGF agents, such as bevacizumab.

However, in this retrospective study, we did not assess mCRC patients who were more likely to respond to bevacizumab therapy.

There are some reasons to explain the results of this study. First, An Anti-p53 antibody is not normally produced as wild type p53 protein induces tolerance of the host. However, TP53 mutation alone is insufficient to trigger anti-p53 antibody production. Only 20–50 % of patients which detectable TP53 mutations produce detectable anti-p53 antibodies [12]. This is attributed to

### Table 4 p53 status and prognosis of colorectal cancer: past literature date

| Reference     | n    | Histology treatment | Methods for determining p53 Ab | IHC | Sequencing | Frequency altered p53 pathway (%) | Prognostic value | Overall survival | Survival | Response |
|---------------|------|---------------------|--------------------------------|-----|------------|----------------------------------|------------------|-----------------|----------|----------|
| LAN YT [10]   | 258  | ACC surgery         | -                              | +   | -          | 37.6 (IHC)                       | univariate       | NA              | NA       | NA       |
| Triantafyllou K [11] | 55   | Adenoma Polypectomy | -                              | +   | -          | 41.8 (DHCD)                      | NA               | murtivariate    | NA       | NA       |
| Wang Q [12]   | 40   | ACC surgery         | -                              | +   | -          | 65 (OHCD)                        | univariate       | NA              | NA       | NA       |
| Hu J [13]     | 120  | ACC biopsy and surgery | -                        | +   | -          | 57 (OHCD)                        | univariate       | NA              | NA       | NA       |
| Grewal H [14] | 66   | ACC surgery         | -                              | +   | -          | 51.5 (IHC)                       | NS               | NA              | NA       | NA       |
| Bouzourene H [15] | 122 | ACC surgery         | -                              | +   | +          | 47 (IHC)                         | univariate       | NA              | NA       | NA       |
| Samowitz W5 [16] | 1464 | ACC biopsy and surgery | -                        | +   | -          | 45.4 (DS)                        | univariate       | NA              | NA       | NA       |
| Chang SC [17] | 167  | ACC surgery         | +                              | -   | +          | 28.1 (Ab)                        | univariate       | NA              | NA       | NA       |
| Angelopoulou K [18] | 229 | ACC biopsy and surgery | +                        | -   | -          | 56.3 (S)                         | murtivariate     | NA              | NA       | NA       |
| Kresnner U [19] | 184  | ACC surgery         | +                              | -   | -          | 32 (Ab)                          | univariate       | NA              | NA       | NA       |
| Suppiah A [20] | 28   | ACC surgery         | +                              | -   | -          | 21.7 (Ab)                        | NS               | NS              | NS       | NS       |
| Keessner U [21] | 294  | ACC biopsy          | +                              | -   | -          | 55 (Ab)                          | NS               | NS              | NS       | NS       |

Ab antibody; IHC immunohistochemistry; S sequencing; ACC advanced colorectal cancer; NA not available; NS not significant

### Table 5 p53 status and prognosis of colorectal cancer: comparison between literature data and the present report

| Reference     | n    | Histology treatment | Methods for determining p53 Ab | IHC | Sequencing | Frequency altered p53 pathway (%) | Prognostic value | Overall survival | Event-free survival | Response |
|---------------|------|---------------------|--------------------------------|-----|------------|----------------------------------|------------------|-----------------|---------------------|----------|
| Popat S [22]  | 967  | CRC Adjuvant        | -                              | +   | -          | 60 (IHC)                         | NS               | NA              | NA                  | NA       |
| Zaana A [23]  | 233  | CRC Adjuvant        | -                              | +   | -          | 53 (IHC)                         | NA               | NS              | NS                  | NA       |
| Ahn MU [24]   | 45   | mCRC chemotherapy   | -                              | +   | -          | 80 (IHC)                         | NA               | NA              | NS                  | NS       |
| Berglund A [25] | 122 | mCRC chemotherapy   | -                              | +   | -          | 60 (IHC)                         | NS               | NA              | NS                  | NS       |
| Ince WL [26]  | 295  | CRC chemotherapy    | -                              | +   | +          | 68 (IHC), 72 (S)                 | NS, NS            | NA              | NA                  | NA       |
| Mollevi DG [27] | 91  | mCRC chemotherapy   | -                              | -   | +          | 50.5 (S)                         | multivariate     | NA              | NA                  | NA       |
| Rosty C [28]  | 56   | mCRC chemotherapy   | -                              | -   | +          | 62.5 (S)                         | univariate       | NA              | NS                  | NS       |
| Westra JL [29] | 220  | CRC Adjuvant        | -                              | -   | +          | 53 (S)                           | NA               | murtivariate     | NA                  | NA       |
| Oden-Gangloff [30] | 64 | mCRC chemotherapy   | -                              | -   | +          | 64 (S)                           | NA               | murtivariate     | NA                  | NA       |
| Present study | 90   | mCRC chemotherapy   | +                              | +   | -          | 40 (Ab), 63 (IHC)                | NS, NS            | NS, NS           | NS, NS              | NS, NS   |

Ab antibody; IHC immunohistochemistry; S sequencing; (m)CRC (metastatic) colorectal cancer; NA not available; NS not significant
the type of mutation, mis-sense mutations is associated with higher antibody production compared with other mutation [13]. Second anti-p53 antibodies most frequency recognize terminal epitopes but not the central domain with majority of the mutation [8]. Third, the differences in individual’s immune systems might relate, the humoral response is independent on the individual’s MHC presentations [8].

The methods used to determine the mutational status of TP53 or KRAS merit discussion. Indeed, the question is whether anti-p53 antibodies are a reliable parameter for the TP 53 mutation status. These antibodies have high specificity but lack sensitivity [4]. They have the same drawbacks as immunohistochemistry because they are absent in patients in whom TP53 mutations negate p53 protein synthesis and accumulation.

In this study we also investigate whether IHC of p53 protein was the predictive factor of chemosensitiviy or not, however there was no relationship between IHC of p53 protein and clinical outcomes.

Other techniques, such as sequencing and functional assays, have been developed to determine the mutation status of TP53 as it applies to CRC. In previous studies, perioperative variations in serum anti-p53 antibody levels have been shown to predict OS (Table 4) [12, 14–24]. However, only the sequencing data were correlated with the level of chemoresistance (Table 5) [4, 11, 25–31]. Anti-p53 antibody has low sensitivity in CRC but is nearly 100 % specific for malignancy. Thus, we believe anti-p53 antibody measurement is suitable and cost-effective for screening a high-risk population and for postoperative cancer surveillance as a guide for earlier detection of recurrence [29].

This study had some limitations. Because of its retrospective and single-center nature, an unknown bias may exist in the findings. Furthermore, we didn’t measure TP53 mutation using sequencing method which is one of the main methods of detect TP53 mutation. When we assess the relationship between TP53 gene mutation and chemoresistance in mCRC patients, we should use other methodologies such as sequencing and functional assays, apart from the anti-p53 antibody status.

Conclusion

Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with fluoropyrimidine, oxaliplatin, plus bevacizumab at first-line chemotherapy. We believe that if we want to know the relationship between the anti-p53 antibody status and chemosensitivity, we should use other methodologies like sequencing, and functional assays, apart from the anti-p53 antibody status.

Abbreviations

(m)CRC: Metastatic colorectal cancer; IHC: Immunohistochemistry; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF: v-Raf murine sarcoma viral oncogene homolog B; MEK: Mitogen-activated protein kinase kinase; ERK: Extracellular signal-regulated kinase; OS: Overall survival; PFS: Progression free survival; Bev: Bevacizumab; RESIST: Response evaluation criteria in solid tumors; ELISA: Enzyme-linked immuno- sorbent assay; ORR: Overall response rate; NA: Not available; HR: Hazard ratio; CI: Confidence Interval; VEGF: Vascular endothelial growth factor; MHC: Major histocompatibility complex.

Competing interests

S. Matsusaka: commercial research grant, Taiho Pharmaceutical Co., Ltd. E. Shinozaki: honoraria from speakers bureau, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co. Ltd, Bristol-Myers Squibb, Takeda Pharmaceutical Co., Ltd. N. Mizunuma: commercial research grant, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co. Ltd, Bristol-Myers Squibb, Takeda Pharmaceutical Co., Ltd., Merck Serono Co., Ltd, ONO Pharmaceutical CO., LTD., Bayer Yakuhin CO., LTD.

All remaining authors have declared no conflicts of interest.

Authors’ contributions

The original manuscript was written by HO. HO and ES and YK and MO and MS and SM and KC and NM performed chemotherapy for mCRC. NY performed immunostaining with anti p53 protein antibody on formalin-fixed paraffin-embedded fragments. All authors contributed to drafting and editing the manuscript. All authors read and approved the final manuscript.

Author details

1. Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Arikae, Koto-ku, Tokyo 135-8550, Japan. 2. Medical Department of Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Received: 29 July 2014 Accepted: 9 October 2015

Published online: 21 October 2015

References

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1998;319:25–32.
2. Shimada H, Okazumi S, Takeda A, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al. Presence of serum p53 antibodies is associated with decreased in vitro chemo sensitivity in patients with esophageal cancer. Surg Today. 2001;31:591–96.
3. Mollevi DG, Serrano T, Ginestà MM, Vallis J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastasis undergoing surgical resection. Gcncriogenesis. 2007;28:141–47.
4. Popat S, Chen Z, Zhao D, Pan H, Hearer N, Chandler L, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Annals of Oncology. 2006;17:1810–17.
5. Lubin R, Schlichtholz B, Teillault JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995;1(12):1463–69.
6. Blanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin C, et al. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Cancer. 2012;12:119.
7. Bazzan V, Agrnese V, Comale S, Calò V, Valerio MR, Latteri MA, et al. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Groupo Oncologico dell’Italia Meridionale (GOMI) prospective study. Ann Oncol. 2005;16 Suppl 4:50–55.
8. Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1085 patients with various cancers. A multi-institutional analysis by Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.
9. Fukushima Y, Yanaka S, Murakami K, et al. High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2011;38:1825–35.
28. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Thymidylate synthase, p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997;70:46–51.

29. Mollevi DG, Serrano T, Ginestà MM, Valls J, Torras J, Navaro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis. 2007;28(8):1241–46.

30. Rosty C, Chazal M, Ettene MC, Letoublon C, Bourgeon A, Delpero JR, et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer. 2001;95(3):162–7.

31. Oden-Gangloff A, Di Fiore F, Biebau F, Lamy A, Bougeard G, Charbonnier F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100(8):1330–35.

10. Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer. World J Gastroenterol. 2013;19(29):4651–70.

11. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5625–33.

12. Angelopoulos K, Paspatis GA, Zizi A, Papaetheodoulis GV, Tzouvala M, Chlouverakis G, et al. p53 protein accumulation and colonic adenoma recurrence. Eur J Gastroenterol Hepatol. 1999;11(5):547–52.

13. Russo A, Bazzan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518–28.

14. Lan YT, Chang SC, Li AF, Lin TC, Chen WS, Jiang JK, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007;22(5):499–506.

15. Triantafyllou K, Paspatis GA, Zizi A, Papaetheodoulis GV, Tzouvala M, Chlouverakis G, et al. p53 protein accumulation and colonic adenoma recurrence. Eur J Gastroenterol Hepatol. 1999;11(5):547–52.

16. Wang Q, Zhao P, Hu Y, Yang G, et al. Prognostic significance of P53 protein expression in patients with colorectal adenocarcinoma. Hua Xi Yi Ke Da Xue Xue Bao. 1998;29(2):182–84.

17. Hu J, Wang Z, Jiang Y. Relations between p53 and p185 expression and prognosis of patients with colon cancers. Zhonghua Zhong Liu Za Zhi. 1996;18(4):247–49.

18. Grewal H, Guillerm JG, Klimstra DS, Cohen AM, et al. p53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum. 1995;38(11):1176–81.

19. Bouzourene H, Gevraz P, Cerottini JP, Benhattar J, Chaubert P, saraga E, Famponna S, p53 and K-ras as prognostic factors for Dukes’ stage B colorectal cancer. Eur J Cancer. 2000;36(8):1088–15.

20. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99(4):597–602.

21. Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK, et al. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int J Colorectal Dis. 2009;24(6):623–28.

22. Kreissner U, Glimelius B, Bergström R, Pålhlman L, Larsson A, Lindmark G, et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer. 1998;77(11):1848–851.

23. Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J, et al. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis. 2008;23(6):595–600.

24. Kreissner U, Lindmark G, Gerdin B, Pålhlman L, Glimelius B, et al. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996;16(2):951–57.

25. Zaanan A, Cuilliere-Dartigues P, Guillou A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.

26. Ahn MJ, Choi JH, Oh HS, Lee YY, Kim IG, Choi HY, et al. Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy. Cancer Res Treat. 2005;37(4):216–22.

27. Berglund A, Schäpfeld M, Hollema H, De Boer JP, Kraak MM, De Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5625–33.

28. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of K-RAS, B-RAF, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97(13):981–89.